These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 16925728

  • 1. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 2. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 3. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 Nov; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 4. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D.
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Dec; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 6. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Dec; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.
    J Med Assoc Thai; 2004 Jul 13; 87(7):760-7. PubMed ID: 15521230
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, Liu C.
    Intervirology; 2010 Jul 13; 53(4):240-6. PubMed ID: 20357493
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.
    HIV Med; 2005 Sep 13; 6(5):353-9. PubMed ID: 16156884
    [Abstract] [Full Text] [Related]

  • 11. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 13; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 12. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr 13; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P, de Górgolas M, Estrada V, Arranz A, Rivas P, Yera C, García R, Granizo JJ, Fernández-Guerrero M.
    Clin Infect Dis; 2004 Oct 01; 39(7):1024-9. PubMed ID: 15472856
    [Abstract] [Full Text] [Related]

  • 14. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D, OzCombo 2 investigators.
    HIV Clin Trials; 2002 Oct 01; 3(3):177-85. PubMed ID: 12032876
    [Abstract] [Full Text] [Related]

  • 15. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ.
    HIV Med; 2007 Jul 01; 8(5):267-70. PubMed ID: 17561871
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.
    J Med Assoc Thai; 2006 Sep 01; 89(9):1472-8. PubMed ID: 17100387
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct 01; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 18. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI, Aboulhab J.
    HIV Med; 2005 Jan 01; 6(1):13-20. PubMed ID: 15670247
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec 01; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodríguez-Rosado R, González-Lahoz J.
    J Hum Virol; 2000 Dec 01; 3(6):335-40. PubMed ID: 11100914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.